alexa A Methodologic Comparison of Invader and Autogenomics INFINITI in Factor-V Leiden and Prothrombin Gene Mutation Testing | OMICS International | Abstract
ISSN: 2376-0311

JBR Journal of Clinical Diagnosis and Research
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

A Methodologic Comparison of Invader and Autogenomics INFINITI in Factor-V Leiden and Prothrombin Gene Mutation Testing

Weyant GW*, Newell JM, Benko FA and Donaldson KJ

Department of Pathology, Penn State Milton S. Hershey Medical Center, Hershey, USA

Corresponding Author:
Weyant GW
Department of Pathology
Penn State Milton S Hershey Medical Center
Hershey, USA
Tel: 717 531-8246
Fax: 717531-7741
E-mail: [email protected]

Received date: February 03, 2014; Accepted date: February 20, 2014; Published date: February 25, 2014

Citation: Weyant GW, Newell JM, Benko FA, Donaldson KJ (2014) A Methodologic Comparison of Invader and Autogenomics INFINITI in Factor-V Leiden and Prothrombin Gene Mutation Testing. J Clin Diagn Res 2:104. doi:10.4172/jcdr.1000104

Copyright: © 2014 Weyant GW, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Collectively, factor V Leiden (FVL, rs6025) and prothromin gene mutation (PGM, rs1799963) are responsible for the majority of inherited thrombophilic states in Caucasians. Patients with inherited thrombophilias are at a greater risk of unprovoked venous thromboembolic events. As such, testing for these abnormalities has become standard of care in the appropriate clinical context.
In this study, we compare the workflow and performance of a non-PCR based method, the Invader® assay, and the INFINITI® assay in FVL and PGM testing. The driving factor behind the methodological comparison was the need to gain efficiency in our molecular diagnostic pipeline. If viable, the INFINITI® platform would allow for rapid expansion of the menu of molecular diagnostic tests performed by our institution.
Methods: To establish concordance between the two assays, forty four and thirty one specimens that had been previously tested with the Invader® assay for FVL and PGM, respectively, were identified.These specimens were subsequently tested on the INFINITI® platform, and results from the two assays were compared.
Results: The INFINITI® Assay produced 100% concordance with the Invader® assay in both FVL (44/44) and PGM (31/31) testing.
Conclusion: These results indicate that the INFINITI® platforms can reliably genotype FVL and PGM.

Keywords

Top